Difference between revisions of "Maprotiline-venlafaxine"

From Psychiatrienet
Jump to: navigation, search
 
Line 3: Line 3:
 
| to = venlafaxine
 
| to = venlafaxine
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
+
{{stopMaprotiline}}
* '''Day 1:''' reduce dosage of maprotiline to 50 mg/day.
 
* '''Day 7:''' reduce dosage of maprotiline to 25 mg/day.
 
* '''Day 14:''' stop dosage of maprotiline.
 
 
| start =  
 
| start =  
* '''Day 14:''' {{startVenla}}
+
* '''Day 15:''' {{startVenla}}
| caveat =
 
|info =
 
{{review}}
 
 
}}
 
}}

Latest revision as of 14:59, 2 November 2015

Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from maprotiline to venlafaxine.

Nietinrijdenbord.png Stop maprotiline
  • Before day 1: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
  • Day 1: reduce dosage of maprotiline to 50 mg/day.
  • Day 7: reduce dosage of maprotiline to 25 mg/day.
  • Day 14: stop dosage of maprotiline.
Eenrichtingbord.png Start venlafaxine
  • Day 15: Start administration of venlafaxine in a normal dosage of 37,5 mg or 75 mg (slow release) /day.


The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.